Adjuvant chemotherapy in colon cancer - Is it worth it?

European Journal of Cancer

Volumn 46, Issue 10, 2010, Pages 1768-1769

  Grothey, Axel ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

Adjuvant therapy; Colon cancer; Survey; Treatment benefit

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; COLON CANCER; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE FREE SURVIVAL; DRUG EFFICACY; GERIATRIC PATIENT; HEALTH CARE COST; HUMAN; INTERVIEW; OVERALL SURVIVAL; PATIENT DECISION MAKING; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; ADJUVANT CHEMOTHERAPY; COLONIC NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS;

EID: 77953287177     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.04.003     Document Type: Note

References (11)

1. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 322 6 (1990) 352-358
2. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 350 23 (2004) 2343-2351
3. Kuebler J.P., Wieand H.S., O'Connell M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 16 (2007) 2198-2204
4. Andre T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 19 (2009) 3109-3116
5. Jackson McCleary N.A., Meyerhardt J., Green E., et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT database. ASCO Meeting Abstr 27 15S (2009) 4010
6. Blinman P., Duric V., Nowak A., et al. Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?. Eur J Cancer 46 10 (2010) 1800-1807
7. Slevin M.L., Stubbs L., Plant H.J., et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300 6737 (1990) 1458-1460
8. Love N., Bylund C., Meropol N.J., et al. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors. ASCO Meeting Abstr 25 18 Suppl (2007) 4020
9. Kerr D., Gray R., Quirke P., et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. ASCO Meeting Abstr 27 15S (2009) 4000
10. Waldman S.A., Hyslop T., Schulz S., et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. Jama 301 7 (2009) 745-752
11. Glas A.M., Roepman P., Salazar R., et al. Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients. ASCO Meeting Abstr 27 15S (2009) 4036